These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23527118)

  • 21. [Assessment of six drug sensitivities in established cell lines of SO-Rb50 and SO-Rb70].
    Zhang P; Feng G; Yi Y; Wu Z; Li Y; Zheng J
    Zhonghua Yan Ke Za Zhi; 1998 Mar; 34(2):109-12. PubMed ID: 11877168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.
    Lu Y; Boswell W; Boswell M; Klotz B; Kneitz S; Regneri J; Savage M; Mendoza C; Postlethwait J; Warren WC; Schartl M; Walter RB
    Sci Rep; 2019 Jan; 9(1):530. PubMed ID: 30679619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
    Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
    PLoS One; 2019; 14(1):e0211268. PubMed ID: 30695050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large-Scale Drug Screening in Patient-Derived IDH
    Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
    Griffiths M; Sundaram H
    Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repositioning approved drugs for the treatment of problematic cancers using a screening approach.
    Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
    PLoS One; 2017; 12(2):e0171052. PubMed ID: 28166232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro.
    Al-Abd AM; Mahmoud AM; El-Sherbiny GA; El-Moselhy MA; Nofal SM; El-Latif HA; El-Eraky WI; El-Shemy HA
    Cell Prolif; 2011 Dec; 44(6):591-601. PubMed ID: 22011009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
    Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
    Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
    He X; Wang Y; Zhu J; Orloff M; Eng C
    Cancer Lett; 2011 Feb; 301(2):168-76. PubMed ID: 21168265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
    BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer.
    Senkowski W; Zhang X; Olofsson MH; Isacson R; Höglund U; Gustafsson M; Nygren P; Linder S; Larsson R; Fryknäs M
    Mol Cancer Ther; 2015 Jun; 14(6):1504-16. PubMed ID: 25911689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor Activity of Novel Signal Transducer and Activator of Transcription 3 Inhibitors on Retinoblastoma.
    Jo DH; Lee S; Bak E; Cho CS; Han YT; Kim K; Suh YG; Kim JH
    Mol Pharmacol; 2021 Jul; 100(1):63-72. PubMed ID: 34016717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing.
    Zhang L; He M; Zhang Y; Nilubol N; Shen M; Kebebew E
    J Clin Endocrinol Metab; 2012 Mar; 97(3):E319-28. PubMed ID: 22170715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.
    Guest ST; Kratche ZR; Irish JC; Wilson RC; Haddad R; Gray JW; Garrett-Mayer E; Ethier SP
    Oncotarget; 2016 Jun; 7(24):36138-36153. PubMed ID: 27153554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma.
    Sinenko IL; Turnell-Ritson RC; Munier FL; Dyson PJ
    Exp Eye Res; 2023 May; 230():109447. PubMed ID: 36940901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HTS384 NCI60: The Next Phase of the NCI60 Screen.
    Kunkel MW; Coussens NP; Morris J; Taylor RC; Dexheimer TS; Jones EM; Doroshow JH; Teicher BA
    Cancer Res; 2024 Aug; 84(15):2403-2416. PubMed ID: 38861359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma.
    Zhao T; Wang C; Huo X; He ML; Chen J
    J Cell Mol Med; 2020 Nov; 24(21):12525-12536. PubMed ID: 33047871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of
    Sime W; Jemaà M; Abassi Y; Lasorsa VA; Bonne Køhler J; Hansson K; Bexell D; Michaelis M; Cinatl J; Strand D; Capasso M; Massoumi R
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
    Pritchard EM; Dyer MA; Guy RK
    Mini Rev Med Chem; 2016; 16(6):430-54. PubMed ID: 26202204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.